Trial design of the EORTC/Lymphoma Study Association/Fondazione Italiana Linfomi H10F/U study in early-stage HL. (A) H10F trial in early-stage favorable HL with 754 patients randomly assigned. (B) H10U trial in early-stage unfavorable HL with 1196 patients randomly assigned. RFs were as follows: age ≥50 years, LMM, elevated erythrocyte sedimentation rate (with B symptoms, >30 mm/h; without B symptoms, >50 mm/h), ≥3 nodal areas. esc, escalated; FU, follow-up.